Lupin, PlushCare expand access to Bacterial Vaginosis Treatment to Meet Patient Needs amid COVID crisis

Bacterial vaginosis is the most common vaginal infection in the U.S. affecting more than 20 million women between the ages of 14 and 49 annually. Symptoms of BV include an unpleasant or fishy odor, a thin milky greyish-white discharge, or excessive discharge, and sometimes itching, burning sensation or irritation. However, some women may have no symptoms. BV is treated with a prescription antibiotic, and if untreated, is associated with an increased risk of pelvic inflammatory disease, HIV, and other sexually transmitted infections.

"As we navigate through these unprecedented times, we are committed to helping women access treatment, information and resources without delay, in order to maintain their health," said Jon Stelzmiller, President – Specialty, Lupin Pharmaceuticals, Inc. "This partnership allows women suffering from BV the ability to speak to a doctor about their symptoms and potentially get treatment without leaving their home or delaying their treatment."

"With the current healthcare landscape, more people are turning to telehealth than we've ever seen before," said Ryan McQuaid, CEO, and Co-Founder of PlushCare. "We are thrilled that Lupin Pharmaceuticals has chosen to partner with us to help women gain access to BV treatment with greater ease."

PlushCare is a virtual health platform offering affordable medical services to patients in all 50 states. Having treated over 225,000 patients and diagnosed over 3,500 medical conditions, PlushCare is changing the medical landscape and offering affordable and accessible healthcare to all.

Read also: Lupin recalls a lot of Metformin Hydrochloride ER tablets in US over cancer-causing impurity